HC Wainwright Has Negative Outlook of PepGen FY2025 Earnings

PepGen Inc. (NASDAQ:PEPG) – Research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of PepGen in a research note issued to investors on Monday, February 24th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($2.96) per share for the year, down from their prior estimate of ($2.42). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s FY2026 earnings at ($2.54) EPS, FY2027 earnings at ($1.99) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.31) EPS.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13.

PEPG has been the subject of several other reports. Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Monday, December 16th. Wedbush dropped their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

PepGen Stock Down 10.5 %

NASDAQ:PEPG opened at $1.53 on Thursday. The firm has a market capitalization of $49.87 million, a P/E ratio of -0.51 and a beta of 1.53. PepGen has a 52 week low of $1.16 and a 52 week high of $19.30. The company has a fifty day moving average of $2.41 and a 200 day moving average of $5.75.

Institutional Investors Weigh In On PepGen

Several hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of PepGen during the third quarter valued at approximately $95,000. Suvretta Capital Management LLC raised its stake in PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after buying an additional 140,000 shares during the last quarter. Walleye Capital LLC purchased a new position in PepGen during the third quarter valued at $519,000. Janus Henderson Group PLC boosted its holdings in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after acquiring an additional 1,794,641 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of PepGen by 76.9% during the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after acquiring an additional 17,618 shares in the last quarter. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.